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Introduction: The early diagnosis of sepsis remains a challenge. Recently, soluble cluster of differentiation 14
subtype (sCD14-ST), also known as presepsin, has been identified as a potential biomarker of sepsis. We performed
a meta-analysis to assess the diagnostic accuracy of presepsin for sepsis in patients with systemic inflammation.
Methods: We systematically searched the PubMed, Embase, Web of Knowledge and Cochrane databases. Studies
were included if they assessed the diagnostic accuracy of presepsin for sepsis in adult patients with systemic
inflammatory response syndrome (SIRS). Furthermore, a 2 × 2 contingency table was constructed based on these
results. Two authors independently judged the studies and extracted the data. The diagnostic accuracy of presepsin
in sepsis was calculated using a bivariate meta-analysis model. The Q-test and I2 index were used to test the
heterogeneity.
Results: Eight studies involving a total of 1,815 patients were included in the present study. The pooled sensitivity,
specificity, diagnostic odds ratio, positive likelihood ratio and negative likelihood ratio were 0.86 (95 % CI: 0.79-0.91),
0.78 (95 % CI: 0.68-0.85), 22 (95 % CI: 10–48), 3.8 (95 % CI: 2.6-5.7), and 0.18 (95 % CI: 0.11-0.28), respectively. The
area under the summary receiver operator characteristic curve was 0.89 (95 % CI: 0.86–0.92). Meta-regression
analysis revealed that consecutive patient selection, sample size and setting significantly accounted for the
heterogeneity of sensitivity.
Conclusions: Our findings suggest that presepsin exhibits very good diagnostic accuracy (AUC=0.89) for the
diagnosis for sepsis. Nevertheless, an overall assessment of all the clinical indexes for sepsis diagnosis and continual
re-evaluation of presepsin during the course of the disease are needed.Introduction
Sepsis is a life-threatening condition that arises when
the body’s response to an infection injures its own tis-
sues and organs [1]. Despite advances in antibiotic ther-
apy and modern life support, the fatality rate of patients
with sepsis has remained as high as 30−60 % [2, 3]. De-
lays in the initiation of antimicrobial treatment are asso-
ciated with worse prognosis [4, 5], which highlights the
importance of timely diagnosis to reduce the morbidity
and mortality of sepsis patients.
Currently, the diagnosis of sepsis is based on the pres-
ence of systemic inflammatory response syndrome
(SIRS) criteria in the presence of a known infection.* Correspondence: ricu301@126.com
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sue injury and innate immune activation can induce
clinical syndromes analogous to sepsis, including mul-
tiple trauma, pancreatitis, burns, and autoimmune dis-
eases. Blood culture is the gold standard for identifying
infectious conditions, but this approach is of limited use
for the early detection of a bloodstream infection due to
the duration of time required to obtain positive cultures,
exclude specimen contamination and identify colonization
[6]. Biomarkers, which were recently introduced among
the inflammatory variables in the diagnostic criteria for
sepsis, could contribute to the prompt identification of
sepsis. However, no ideal biomarker has yet been identified
with sufficient clinical sensitivity or specificity for the diag-
nosis of sepsis [7]. An ideal biomarker is still needed to ac-
curately differentiate sepsis from non-infectious SIRS in a
timely and economic manner.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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glycoprotein expressed mainly on the membrane surface
of monocytes/macrophages. CD14 is also minimally dis-
tributed on the cell surface of neutrophils (mCD14) and
serves as a specific receptor for complexes of lipopolysac-
charides (LPSs) and LPS-binding proteins (LPBs). The
LPS-LBP-CD14 complex is released into the circulation
by shedding CD14 from the cell membrane, yielding sol-
uble CD14 (sCD14), which is also directly secreted by he-
patocytes [8, 9]. During inflammation, plasma protease
activity generates (sCD14) fragments. The 64-amino acid
N-terminal fragments constitute the sCD14 subtype
(sCD14-ST), which has recently been renamed presepsin
[10]. Presepsin has recently been reported to increase in
response to the severity of bacterial infections. The plasma
levels of presepsin specifically increase during sepsis, and
less intensively, during SIRS. An increasing number of
studies have demonstrated the ability of presepsin to serve
as a valuable marker in sepsis diagnosis [11–18]. In light
of the above findings, we aimed to assess the value of pre-
sepsin for the diagnosis of sepsis by performing meta-
analysis of relevant studies of diagnostic test accuracy. To
the best of our knowledge, this approach has not been pre-
viously performed.
Methods
Search strategy and selection criteria
We systematically searched studies in the PubMed,
Embase, Web of Knowledge and the Cochrane Library
databases. The search terms were as follows: (“presepsin”
or “soluble CD14 subtype” or “sCD14-ST”) AND (sepsis
OR “bacterial infection” OR “systemic inflammatory re-
sponse syndrome” OR “SIRS”). No language restriction or
publication date restrictions were applied. We further
reviewed the reference lists of the selected articles to ob-
tain potentially relevant articles.
Eligible studies were required to include a well-defined
reference standard for the patients involved. For the in-
cluded studies, the sepsis group was defined according
to the criteria of the American College of Chest Physi-
cians/Society of Critical Care Medicine [19, 20], whereas
the other patients were required to meet the criteria for
SIRS. Additionally, the studies included data on the diag-
nostic accuracy of presepsin for sepsis in adult patients
(>18 years old) with SIRS. Furthermore, a 2 × 2 contin-
gency table was constructed based on the results. For
studies providing multiple presepsin cutoff values for
diagnostic accuracy, the data providing the maximum
overall accuracy were chosen. For studies that evaluated
the diagnostic accuracy of presepsin levels at multiple
time points, we chose the data based on the initial pre-
sepsin level. Reviews, letters, commentaries, correspond-
ence, case reports, conference abstracts, expert opinions,
editorials and animal experiments were excluded.Articles involving paediatric patients were also excluded.
Two investigators (Zhang X and Liu D) independently
performed the search strategy and evaluated the studies.
Any disagreement was resolved by a third opinion.
Data extraction and quality assessment
The following descriptive data were extracted from the
original studies: the name of the first author, publication
year, country of origin, study design, clinical setting, se-
verity of sepsis, control patients, sample size, prevalence
of sepsis, the percentage of male patients, average age,
cutoff points, and the true positive (TP), false positive
(FP), false negative (FN), and true negative (TN) rates,
sensitivity (SEN) and specificity (SPE) of the data. We
contacted the corresponding authors if the necessary
data were not presented or required clarification. We
used a revised tool for the Quality Assessment of Diag-
nostic Accuracy Studies (QUADAS) checklist [21] to as-
sess the quality of the included studies. Furthermore, the
studies were grouped according to Sackett and Haynes’
classification of diagnostic studies [22]. Utilizing this
classification, phase 1 studies were those that compared
the difference in test results between patients with the
target disorder and healthy individuals. Phase 2 studies
were those that examined how the index test differenti-
ated between patients with and without the target dis-
order. Phase 3 studies were those that assessed the test’s
real-life performance in patients in whom the disorder
was suspected.
Statistical analysis
All statistical analyses were performed using the
MIDAS module for STATA software, version 12.0
(Stata Corporation, College Station, TX, USA). P values
less than 0.05 were considered statistically significant.
A bivariate random effects regression model [23] was
used to calculate the pooled SEN, SPE, diagnostic odds
ratio (DOR), positive likelihood ratio (PLR), and nega-
tive likelihood ratio (NLR). We also constructed a sum-
mary receiver operator characteristic (SROC) curve by
plotting the individual and summary points of SEN and
SPE to assess overall diagnostic accuracy [24]. Fagan’s
nomogram was used to calculate the post-test probability
(PTP) [25]. The Q test and I2 index were calculated to as-
sess between-study heterogeneity [26, 27]. I2 greater than
50 % was considered sustainable heterogeneity among
studies.
In addition to the proportion of heterogeneity that was
likely due to the threshold effect, univariate meta-
regression analysis and subgroup analysis were per-
formed to explore the sources of potential heterogeneity
in SEN and SPE. The covariates included the following:
prevalence (prevalence <50 % or ≥50 %), sample size
(sample size <100 or ≥100), blinding (whether sepsis
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of the presepsin level), setting (whether the study was per-
formed in the emergency department (ED) or intensive
care unit (ICU)), study design (whether patients were re-
cruited consecutively), and comorbidities (whether the
studies excluded patients who had comorbidities that were
likely to influence presepsin levels). Subgroup analysis was
restricted to ED patients. Publication bias was tested by
Deek’s funnel plot.
Results
Our database search retrieved 185 articles, 172 of which
were eliminated for various reasons based on the title
and abstract, leaving 13 studies that were scrutinized in
a full-text review. Among the 13 studies, one study in-
vestigated the prognostic value of presepsin in sepsis,
one could not be used to reconstruct the 2 × 2 table,
and three were performed using an ineligible design (i.e.,
they evaluated the diagnostic accuracy of presepsin
based on samples that were collected at multiple time
points but not every individual sample). In total, eight
studies fulfilled our eligibility criteria and were included
in the final analysis (Fig. 1). We did not identify any add-
itional relevant articles in the bibliographies of the ori-
ginal articles.
Characteristics of the included studies
The included studies were published between 2012 and
2014. Four studies [11, 14, 16, 18] were conducted in
Europe, and four [12, 13, 15, 17] were conducted inFig. 1 Flow chart of study selectionAsia. A total of 1,815 patients were included, and SIRS
criteria were fulfilled in 1,690 patients, including 1,165
patients with septis and 525 patients with non-infectious
SIRS. Four studies recruited a group of well-matched (by
age and sex) patients without SIRS (60 patients in
Behnes [11], 25 patients in Kweon [12], 100 patients in
Liu [13], and 70 patients in Vodnik [14]) as controls,
and two studies [12, 13] included the control patients as
well as the SIRS patients in the non-sepsis group in a
2 × 2 contingency table when analysing the diagnostic
accuracy of presepsin for sepsis. The mean age of the
patients varied between 54.4 and 79.42 years, and the
proportion of male patients ranged from 50.0 to 66.3.
The prevalence of sepsis varied from 16.4 % to 79.2 %.
The most frequent source of sepsis was pulmonary in-
fection. Six studies [12–14, 16–18] were performed in
the ED, one [11] in the ICU, and one [15] in the ED
and ICU. All included studies recruited a mix of med-
ical and surgical patients. One study [12] excluded pa-
tients with comorbidities (e.g., chronic renal failure or
a history of resuscitation and trauma) that could influ-
ence presepsin levels. Presepsin levels were measured
with a chemiluminescent immunoassay on a PATH-
FAST immunoanalyzer [28, 29] in all studies. The test
threshold ranged from 317 to 729 pg/ml. Details of all
eight studies are presented in Table 1. The optimal cut-
off point was retrospectively determined based on the
ROC curve. The mean cutoff for presepsin in the in-
cluded studies was 560 pg/ml (IQR 317–729).
Study quality and publication bias
Studies were grouped according to Sackett and Haynes’
classification for diagnostic studies: two were phase 2
studies (group 1) [12, 13], and six were phase 3 studies
(group 2) [11, 14–18]. All studies included a prospective
cohort. Two [15, 18] studies were multicentre trials. One
study [13] consecutively enrolled patients. Two studies
[12, 13] excluded patients with comorbidities that could
influence presepsin levels. The QUADAS checklists are
presented in Fig. 2. On average the overall QUADAS
scores of all studies met 10 of the 14 criteria, which sug-
gests that the studies were of high quality. Deek’s funnel
plot is presented in Fig. 3. No significant publication bias
was observed (p = 0.31).
Data synthesis and meta-analysis
The pooled SEN and SPE were 0.86 (95 % CI: 0.79, 0.91)
and 0.78 (95 % CI: 0.68, 0.85), respectively (Fig. 4). The PLR
and NLR were 3.8 (95 % CI: 2.6, 5.7) and 0.18 (95 % CI:
0.11, 0.28), respectively (Fig. 5). The DOR was 22 (95 % CI:
10, 48). The area under the SROC curve was 0.89 (95 % CI:
0.86, 0.92) (Fig. 6). Figure 7 presents Fagan’s nomogram for
likelihood ratios, and the results indicate that the use of
presepsin in the detection of sepsis increased the post-
Table 1 Characteristics of included studies
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859 79.2 66.3 79.42 (58–78) 317 481 40 199 239 70.8 85.8
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60 50 58.3 54.4 ± 15.5 630 30 2 0 28 100 93
Endo [15] 2012 Japan MPR ED and ICU NA No 185 62.1 59.5 71.8 (17–98) 600 101 13 14 57 87.8 81.4
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Romualdo [16]
2014 Spain PR ED NA No 226 16.4 58.4 67 ± 26 729 30 70 7 119 81.1 63
Ishikura [17] 2014 Japan PR ED Sepsis, severe sepsis
and septic shock
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Ulla [18] 2013 Italy MPR ED Sepsis and septic
shock
No 189 56.1 61.4 64.4 (19–99) 600 84 32 22 51 78.95 61.9




96 84.4 63.1 65.89 (20–88) 530 73 6 8 9 90 60
PR prospective recruitment, MPR multicentre prospective recruitment, CR consecutive recruitment, ED emergency department, NA not available TP true positive, FP false positive, TN true negative, FN false negative,









Fig. 2 Proportion of Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool criteria fulfilled by the included studies
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duced the post-probability to 4 % when the results were
negative. The mean cutoff for presepsin in the included
studies was 560 pg/ml (IQR 317–729).
Six studies comprising 838 patients were included in
group 2 studies (Table 1). We performed a subgroup ana-
lysis restricted to this group because the studies were re-
stricted to patients who were most likely to be encountered
by clinicians and who were more informative for routineFig. 3 Deek’s funnel plot asymmetry test for publication bias. No publicatioclinical practice. The pooled SEN and SPE were 0.89 (95 %
CI: 0.81, 0.94) and 0.75 (95 % CI: 0.64, 0.84), respectively.
The PLR and NLR were 3.6 (95 % CI: 2.2, 5.8) and 0.15
(95 % CI: 0.08, 0.29), respectively. The DOR was 24 (95 %
CI: 8, 71). The area under the SROC curve was 0.90 (95 %
CI: 0.87, 0.92). The I2 test results for the pooled SEN and
SPE were 68.22 % and 84.90 %, respectively.
There was substantial heterogeneity among the stud-
ies. The I2 test results for the pooled SEN and SPE weren bias was detected (p = 0.31)
SENSITIVITY (95% CI)
Q = 73.60, df = 7.00, p =  0.00
I2 = 90.49 (85.35 - 95.63)
0.86 (0.79 - 0.91)
0.88 (0.78 - 0.94)
0.71 (0.67 - 0.74)
1.00 (0.88 - 1.00)
0.88 (0.80 - 0.93)
0.81 (0.65 - 0.92)
0.91 (0.78 - 0.97)
0.79 (0.70 - 0.87)














Q = 85.07, df = 7.00, p =  0.00
I2 = 91.77 (87.50 - 96.04)
0.78 (0.68 - 0.85)
0.82 (0.68 - 0.92)
0.86 (0.81 - 0.90)
0.93 (0.78 - 0.99)
0.81 (0.70 - 0.90)
0.63 (0.56 - 0.70)
0.77 (0.61 - 0.89)
0.61 (0.50 - 0.72)













Fig. 4 Forrest plot of the sensitivity and specificity of presepsin for the diagnosis of sepsis
Fig. 5 Positive and negative likelihood ratios. The positive likelihood ratio and negative likelihood ratio were 3.8 (95 % CI: 2.6, 5.7), 0.18 (95 % CI:
0.11, 0.28), respectively LUQ left upper quadrant, RUQ right upper quadrant, LLQ left lower quadrant, RLQ right lower quadrant, LRP likelihood
ratio positive, LRN likelihood ratio negative
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Fig. 6 Summary receiver operating characteristic graph of included studies. SEN sensitivity, SPE specificity
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for the bivariate model were 94 % (95 % CI: 85, 99). The
proportion of heterogeneity likely caused by the threshold
effect was small (0.07), whereas the variations in SEN and
SPE were related to differences in the cutoff points for
presepsin that were used in the included studies.
Univariate meta-regression analysis and subgroup ana-
lysis were performed to explore the sources of potential
heterogeneity in SEN and SPE. Patient blinding, preva-
lence, setting, consecutive patient recruitment, and sample
size were used as covariates. Meta-regression revealed that
consecutive recruitment, sample size, and setting signifi-
cantly accounted for the heterogeneity of sensitivity
(Fig. 8). The subgroup analysis restricted to ED patients
revealed that the pooled SEN and SPE were 0.85 (95 % CI:
0.77, 0.92) and 0.78 (95 % CI: 0.69, 0.88), respectively.
Discussion
Sepsis is a common problem in critically ill patients.
Early diagnosis and early treatment are essential for the
clinical course and the outcome of patients with sepsis.
Given that a large proportion of critically ill patients ex-
hibit SIRS, the ability to accurately distinguish between
SIRS and sepsis, which is defined as SIRS as a result of
bacterial infection, has become one of the holy grails of
critical care medicine.
Currently, no recommendation can be given for the
use of biomarkers to differentiate sepsis from non-infectious SIRS [30]. Many biomarkers, particularly pro-
calcitonin (PCT) and C-reactive protein (CRP), are
widely used to identify sepsis in current clinical practice
[31, 32]. In comparison with CRP, PCT seems to be a bet-
ter marker to differentiate sepsis from non-infectious
SIRS. However, two published meta-analyses concluded
that the SEN and SPE of PCT varies in the diagnosis of
sepsis, leading to questions of the ability of PCT to distin-
guish sepsis from SIRS [33, 34]. Presepsin was recently
identified as a molecule involved in the inflammatory re-
sponse [35] and represents a promising diagnostic bio-
marker with high SEN and SPE.
The primary finding of our meta-analysis is that presep-
sin exhibits very good diagnostic accuracy for distinguish-
ing patients with sepsis from those with systemic
inflammatory disease. Specifically, in our primary analysis
involving all studies that evaluated presepsin in adults with
and without sepsis, the area under the SROC curve was
0.89, which was greater than the results of published
meta-analyses of the use of PCT and soluble triggering re-
ceptor expressed on myeloid cells-1 (sTREM-1) for the
diagnosis of sepsis [33, 34, 36]. The pooled SEN and SPE
were 86 % and 78 %, respectively. To our knowledge,
presepsin exhibited the highest sensitivity among the
proposed biomarkers in differentiating sepsis form other
non-infectious SIRS. To date, no biomarkers have exhib-
ited sufficient (greater than 90 %) sensitivity to distinguish
sepsis from SIRS in these critically ill adult patients.
Fig. 7 Fagan’s nomogram for calculation of post-test probabilities.
Fagan’s nomogram for presepsin illustrates post-test probability with
fixed pre-test probability of 20 % for sepsis. LR likelihood ratio, pos
positive, neg negative
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patients with sepsis should be detected within 6 hours,
followed by antibiotic treatment within 1 hour after the
diagnosis of sepsis [37]. Generally, PCT increases 4
hours after infection, slowly reaching a plateau at 8–24
hours and peaking one day after infection. Compared
with PCT, presepsin increases at 2 hours post-infection
in the cecal ligation and puncture (CLP) sepsis model
and peaks at 3 hours [29]. Presepsin can be detected in
the early stage of infection using rapid dosage methods
based on chemiluminescence enzyme immunoassay,
which are available and permit automated measurements
in 1.5 hours [38].
The exclusion of reviews, letters, commentaries, cor-
respondence, case reports, conference abstracts, expert
opinions, editorials and reports of animal experiments
may have contributed to publication bias. However, we
tested for this, and no significant publication bias was
observed in our study (Fig. 3).Marked statistical heterogeneity was present in all ana-
lyses, a fact that must not be overlooked in the interpret-
ation of the above findings. We observed significant
heterogeneity in SEN and SPE among the studies ana-
lysed. Consecutive patient recruitment, sample size, set-
ting and excluded patients substantially affected the SEN
of the diagnosis of sepsis in the meta-regression analysis,
and none of the variables affected the SPE of diagnosis
of bacterial infection in the meta-regression analysis. Ac-
cording to Sackett and Haynes’ classification [22], the
index test in group 1 is developed in an ideal situation
against a validation set (group 2) in which the perform-
ance is tested in a more realistic clinical context. Group
2 studies are the most informative for clinical practice,
as they are designed to resemble the real-world setting
of routine clinical practice by restriction to patients who
are the most likely to be encountered by clinicians. In
this meta-analysis, six of the included studies were clas-
sified as group 2 studies. Additionally, we performed
subgroup analysis restricted to group 2. The pooled sen-
sitivity, DOR and AUC of the six studies (11, 14–18)
were similar to corresponding values in the other stud-
ies. In particular, the pooled AUC indicated high diag-
nostic accuracy (AUC ≥0.9) [39]. All of the studies
included involved a prospective cohort, and two were
multicentre studies, underlining the high quality of these
studies. The test results obtained by the prospective re-
cruitment (PR) study design method achieved more real-
istic results than that obtained by the consecutive
recruitment (CR) method. Therefore, satisfactory results
could be achieved in the future by implementing more
prospective studies.
Likelihood ratios and PTPs are also relevant for clini-
cians, as they provide information on the likelihood of a
patient with a positive or negative test actually exhibiting
sepsis. In our study, with a hypothetical pretest probabil-
ity of 20 % and a PLR of 3.8, detecting presepsin for sep-
sis diagnosis would raise the PTP to 49 %, with an NLR
of 0.18. Detecting presepsin reduced the PTP to 4 %
(Fig. 7), demonstrating that the application of the pre-
sepsin test was advantageous in the diagnosis of sepsis.
Additionally, all included studies recruited a mix of
medical and surgical patients. Our findings can therefore
be generalized to patients from different countries as
well as to different admission categories.
Delayed resuscitation is reportedly significantly asso-
ciated with a high risk of death [40, 41], and rapidly ini-
tiating the appropriate therapeutic interventions upon
the patient’s arrival to the ED is critical. Thus, we per-
formed subgroup analysis restricted to ED patients to
evaluate the diagnostic accuracy of presepsin. The
pooled SEN and SPE were 0.85 (95 % CI: 0.77, 0.92)
and 0.78 (95 % CI: 0.69, 0.88), respectively, nearly equal
to the overall results.
Fig. 8 Univariate meta-regression and subgroup analysis
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preting the findings of this meta-analysis. First, despite
the extensive literature search, the number of included
studies was small; however, the number of patients en-
rolled was satisfactory (n = 1,815), thereby decreasing
type II error. Second, we could not determine the opti-
mized cutoff value because we failed to obtain the raw
data to map the ROC curve. In all studies, the optimal
cutoff point was retrospectively determined based on the
ROC curve. The cutoff points varied greatly among the
studies, despite using the same presepsin assay. A reason
for this discrepancy may be differences in study design,
especially the patient inclusion criteria. Falsely elevated
values of presepsin or PCT are observed in conditions of
chronic renal failure or a history of resuscitation and
trauma. One study [12] excluded patients with these co-
morbidities, but the others did not. Thus, future re-
search should be designed in consideration of how
comorbidities may influence presepsin levels to confirm
an optimal cutoff point for clinical use. Third, due to the
small number of eligible studies and the lack of neces-
sary data reported in the original publications, we couldnot specifically analyse patients with different conditions
(e.g., different severities of sepsis or different sites of in-
fection) to distinguish the sepsis, nor could we deter-
mine the therapeutic decisions in the individual patient.
Last, it is possible that presepsin may perform differently
in sepsis caused by gram-positive, gram-negative, or fun-
gal pathogens. Hence, both the clinical characteristics of
the enrolled patients as well as the local microbiological
profile in included studies are likely to affect the value of
presepsin in predicting sepsis. However, we were unable
to explore this further because the necessary information
was largely unavailable in the studies.
Conclusions
Despite these limitations, our study is the first compre-
hensive meta-analysis to date that assesses the diagnostic
accuracy of presepsin for sepsis in patients with SIRS.
The results demonstrated that presepsin may be a reli-
able biomarker for sepsis because of its good overall
diagnostic performance. However, presepsin cannot be
recommended as the single definitive test for sepsis diag-
nosis according to the current data. Clinicians must
Zhang et al. Critical Care  (2015) 19:323 Page 10 of 11comprehensively evaluate the condition of each patient
and should incorporate an overall assessment of the
clinical indexes for sepsis diagnosis rather than focusing
only on a single biomarker-based approach. Moreover,
continuous re-evaluation during the course of the dis-
ease is advisable.
Key messages
 The present study showed that the pooled sensitivity
and specificity of presepsin for sepsis diagnosis was
0.86 and 0.78, respectively. The area under the
SROC curve was 0.89
 Presepsin has very good diagnostic accuracy
(AUC = 0.89) for the diagnosis for sepsis in
patients with SIRS. However, it cannot be
recommended as the single definitive test for
sepsis diagnosis according to current data
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